Plain-English translation of NCT07111182 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new surgical device called HIVEN® that works during brain tumor removal surgery. The device detects a special fluorescent dye (5-ALA, also known as Gleolan) that highlights tumor tissue, helping surgeons see and remove cancer more completely. The device has already been used successfully in Europe and is now being tested in the United States to make sure it works safely and effectively for patients in American hospitals.
Current methods for surgeons to identify tumor tissue during brain surgery have limitations. This new device aims to give surgeons better real-time information during the operation, potentially helping them remove more tumor while protecting healthy brain tissue.
You likely qualify if…
You likely don't qualify if…
If you qualify, the research team will talk with you before your scheduled brain surgery to explain the study. You will sign a consent form confirming you understand what the study involves. During your surgery, your surgeon will use the new HIVEN® device as part of the standard surgical procedure. After surgery, the research team will gather information about how well the device worked and collect feedback from your surgical team about their experience using it.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States